EP2056830A4 - Spezielle zusammensetzungen zur behandlung bzw. prävention des metabolischen syndroms - Google Patents

Spezielle zusammensetzungen zur behandlung bzw. prävention des metabolischen syndroms

Info

Publication number
EP2056830A4
EP2056830A4 EP07803696A EP07803696A EP2056830A4 EP 2056830 A4 EP2056830 A4 EP 2056830A4 EP 07803696 A EP07803696 A EP 07803696A EP 07803696 A EP07803696 A EP 07803696A EP 2056830 A4 EP2056830 A4 EP 2056830A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
metabolic syndrome
compositions useful
useful especially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07803696A
Other languages
English (en)
French (fr)
Other versions
EP2056830A1 (de
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Corp
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of EP2056830A1 publication Critical patent/EP2056830A1/de
Publication of EP2056830A4 publication Critical patent/EP2056830A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07803696A 2006-08-28 2007-08-22 Spezielle zusammensetzungen zur behandlung bzw. prävention des metabolischen syndroms Withdrawn EP2056830A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20060768A FI20060768A0 (fi) 2006-08-28 2006-08-28 Erityisesti metabolia-oireyhtymän hoitoon tai ehkäisyyn soveltuvia koostumuksia
PCT/FI2007/000206 WO2008025870A1 (en) 2006-08-28 2007-08-22 Compositions useful especially for treatment or prevention of metabolic syndrome

Publications (2)

Publication Number Publication Date
EP2056830A1 EP2056830A1 (de) 2009-05-13
EP2056830A4 true EP2056830A4 (de) 2011-01-12

Family

ID=36950669

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07803696A Withdrawn EP2056830A4 (de) 2006-08-28 2007-08-22 Spezielle zusammensetzungen zur behandlung bzw. prävention des metabolischen syndroms

Country Status (3)

Country Link
EP (1) EP2056830A4 (de)
FI (1) FI20060768A0 (de)
WO (1) WO2008025870A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023207A1 (en) * 2007-08-13 2009-02-19 Synvista Therapeutics, Inc. Thiazolium compounds for treating gastrointestinal complications
WO2009051804A1 (en) * 2007-10-18 2009-04-23 Synvista Therapeutics, Inc. Thiazolium compounds for treating or preventing diseases associated with insulin resistance
EP2357252A4 (de) 2008-09-03 2012-05-16 Univ Barcelona Autonoma Verfahren und zusammensetzungen zur behandlung und diagnose einer hämorrhagischen umwandlung
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
US20180360808A1 (en) 2015-12-07 2018-12-20 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
US20220354847A1 (en) * 2019-09-26 2022-11-10 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Thiamine therapy for fatty liver associated diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558050A (en) * 1984-03-01 1985-12-10 University Of Florida Treatment of metabolic disorders with dichloroacetate-thiamine preparations
EP0511587A1 (de) * 1991-04-26 1992-11-04 Takeda Chemical Industries, Ltd. Schlankmachende Zusammensetzung
EP0808163B1 (de) * 1995-01-18 2003-07-23 Alteon, Inc. Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
DE19629803A1 (de) * 1996-07-24 1998-01-29 Woerwag Pharma Gmbh Arzneimittel zur Behandlung von Neuropathien
DE19629802A1 (de) * 1996-07-24 1998-01-29 Woerwag Pharma Gmbh Arzneimittel zur Behandlung von Neuropathien
DE10353535A1 (de) * 2003-11-14 2005-06-16 Bayer Healthcare Ag Vitaminkombination, enthaltend Benfotiamin
CA2549029A1 (en) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions for treatment or prevention of metabolic syndrome
WO2005095391A1 (en) * 2004-03-24 2005-10-13 Array Biopharma Inc. Thiazoliums as transketolase inhibitors
JP2006008576A (ja) * 2004-06-25 2006-01-12 Kosei Tanaka ヘキサミン生合成経路活性化抑制剤
US20060089316A1 (en) * 2004-10-25 2006-04-27 Brown Truman R Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2008025870A1 *

Also Published As

Publication number Publication date
WO2008025870A1 (en) 2008-03-06
FI20060768A0 (fi) 2006-08-28
EP2056830A1 (de) 2009-05-13

Similar Documents

Publication Publication Date Title
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
ZA200902374B (en) Compositions useful for the treatment of diabetes
EP1871331A4 (de) Zusammensetzung zur behandlung der menopause
IL199903A0 (en) Compositions comprising a synergistic combination of agents for treating metabolic syndrome
IL187999A0 (en) Compositions for the treatment of persistent infections
ZA200900388B (en) Compositions and methods for the treatment of mucositis
PL2104674T3 (pl) Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym
IL210997A0 (en) Compositions for the treatment of mrsa and uses thereof
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
IL243294A0 (en) Compounds and compositions for the treatment of cancer
GB0909297D0 (en) Composition for the treatment of skin conditions
LT2111855T (lt) Antibakteriės kompozicijos, skirtos viršutinių ir apatinių kvėpavimo takų infekcijų gydymui
IL196901A0 (en) Compositions for the treatment of chronic degenerative inflammatory conditions
PL2091537T3 (pl) Kompozycja farmaceutyczna do leczenia arteriopatii włośniczkowej
EP2174956A4 (de) Zusammensetzungen für eine antifibrinolysetherapie
IL182055A0 (en) Agent for prophylaxis or treatment of metabolic syndrome
GB0917745D0 (en) Compositions for the prevention or treatment of migraine
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
GB0612273D0 (en) Prevention of muscle atrophy
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes
HUP0500947A2 (en) Composition for treatment of paradontosis
GB0619891D0 (en) Pharmaceutical composition of risedronate
PL1996207T3 (pl) Kompozycje zawierające chitozan przydatne do kompleksowego leczenia terapeutycznego lub kompleksowej profilaktyki zespołu metabolicznego
IL193686A0 (en) Agent for prevention/treatment of irritable bowel syndrome
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOTIE THERAPIES OYJ

A4 Supplementary search report drawn up and despatched

Effective date: 20101213

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/426 20060101ALI20101207BHEP

Ipc: A61P 9/10 20060101ALI20101207BHEP

Ipc: A61P 3/00 20060101ALI20101207BHEP

Ipc: C07D 277/24 20060101ALI20101207BHEP

Ipc: A23L 1/302 20060101ALI20101207BHEP

Ipc: A61K 31/675 20060101ALI20101207BHEP

Ipc: A61K 31/51 20060101AFI20080409BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110612